Sign In

Sylvain Sachot

Partner chez Asabys Partners

Sylvain Sachot is an investment professional with extensive experience in the healthcare and biotechnology sectors. Here's a detailed profile of his background and current role:

Professional Background

Sylvain Sachot is currently a Partner at Asabys Partners, a venture capital firm specializing in healthcare investments.13 He joined Asabys at its inception in 2018, bringing with him valuable experience from his previous role at Ysios Capital.1

Education

Sachot's educational background includes:

  • Ph.D. in Molecular Medicine from the University of Nantes (2009)1
  • Master's degree in Biotechnology (with honors) from University Paris XII1
  • MBA from Esade Business School in Barcelona (2014)14

Career Highlights

Academic Experience:: Prior to his venture capital career, Sachot spent a decade in academic research, focusing on gene therapy and regenerative medicine. He completed a postdoctoral fellowship at the Mount Sinai School of Medicine in New York.3

Investment Experience:: At Asabys Partners, Sachot is involved in sourcing, executing, and managing investments in the biopharma and medtech sectors.3

Board Positions

Sylvain Sachot serves on the board of directors for several companies, including:

  • Gradient Denervation Technologies
  • Anaconda Biomed
  • Orikine Bio

He also holds observer positions on the boards of SpliceBio and Medlumics.3

Gradient Denervation Technologies Investment

Sachot played a key role in Asabys Partners' recent investment in Gradient Denervation Technologies. The company secured a €14 million Series A funding round led by Sabadell Asabys, with Sachot commenting on the potential of Gradient's technology to become a first-in-class treatment for patients suffering from heart failure and elevated pulmonary pressures.2

Skills and Expertise

Sachot has a broad understanding of the biopharma and medtech industries, with particular expertise in:

  • Gene and cell therapy
  • Lysosomal storage disorders
  • Investment sourcing and due diligence

He is proficient in French, English, and Spanish.1

Highlights

Sep 7 · asebio.com
Gradient Denervation Technologies closes €14m Series A led by ...
Sep 7 · Business Wire
Gradient Denervation Technologies closes €14m Series A led by ... - Business Wire
Gradient Denervation Technologies closes €14m Series A led by ... - Business Wire
Dec 4 · Business Wire
Anaconda Biomed S.L. Secures €20 Million Round of Funding - Business Wire

Related Questions

What are Sylvain Sachot's main responsibilities at Asabys Partners?
How did Sylvain Sachot transition from academia to investment directing?
What are the key projects Sylvain Sachot has been involved in at Asabys Partners?
How does Sylvain Sachot's background in biotechnology influence his investment strategies?
What makes Gradient Denervation Technologies' technology unique according to Sylvain Sachot?
Sylvain Sachot
Sylvain Sachot, photo 1
Sylvain Sachot, photo 2
Add to my network

Location

Spain